US Stock MarketDetailed Quotes
EVLO Evelo Biosciences
- 0.000
- +0.000+33.33%
15min DelayClose Nov 4 16:00 ET
7.59KMarket Cap0.00P/E (TTM)
0.000High0.000Low657Volume0.000Open0.000Pre Close0.26Turnover0.01%Turnover Ratio0.00P/E (Static)18.98MShares0.76052wk High0.00P/B3.54KFloat Cap0.00052wk Low--Dividend TTM8.86MShs Float398.566Historical High--Div YieldTTM0.00%Amplitude0.000Historical Low0.000Avg Price1Lot Size
About Evelo Biosciences Company
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Company Profile
SymbolEVLO
Company NameEvelo Biosciences
Listing DateMay 9, 2018
Issue Price16.00
Founded2014
CEOMr. Craig R. Jalbert
MarketPink Market
Employees66
Fiscal Year Ends12-31
AddressOne Kendal Square, 600/700,Suite 7-201
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-577-0300
Websitehttp://www.evelobio.com
Company Executives
- Name
- Position
- Salary
- Craig R. Jalbert
- President, Chief Executive Officer, Director, Corporate Secretary, Principal Accounting Officer and Principal Financial Officer
- --
- Duncan McHale
- Chief Medical Officer
- --
- Mark D. Plinio
- Chief Commercial Officer
- --
- Mark Bodmer
- Chief Scientific Officer and President, Research and Development
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data